ReviewFrontiers in pharmacology2026
Review of clinical advances in the procedural sedation application of remimazolam.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: With the ongoing advancement of comfort-oriented healthcare, procedural sedation is increasingly applied in clinical practice. As a novel benzodiazepine derivative, remimazolam offers distinct advantages in procedural sedation. This paper aims to thoroughly examine its pharmacological properties and key clinical applications, providing systematic guidance for rational clinical use while promoting further adoption and development of this medication in relevant fields. Methods: Conduct a systematic analysis and summary by examining the pharmacological characteristics of remimazolam, including its mechanism of action and pharmacokinetic properties, and integrating its application scenarios, dosing regimens, and comparative efficacy data across various clinical sedation procedures. Results: Remimazolam, with its unique pharmacological advantages-such as rapid onset, short duration of action, inactive metabolites, and high safety profile-demonstrated excellent sedative efficacy and tolerability in clinical procedural sedation. It effectively meets sedation requirements across diverse procedural settings while exhibiting a low incidence of adverse reactions, thereby offering significant clinical value. Discussion: As a novel benzodiazepine derivative, remimazolam overcomes the limitations of traditional sedatives, offering a new option for procedural sedation in palliative care. Its unique pharmacologic properties ensure rapid onset, controllable duration of action, and high safety, thereby enhancing clinical procedural efficiency and patient experience. This systematic review of its clinical applications provides scientific evidence for the rational and standardized use of remimazolam in clinical practice. Future research should focus on expanding its application in more complex clinical scenarios and conducting long-term safety and efficacy studies to further promote the widespread use of remimazolam in procedural sedation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.